Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, CONICET. Av. Pueyrredon 1640 (C1118AAT), Buenos Aires, Argentina.
Charité-Center for Internal Medicine and Dermatology, Division of General Internal and Psychosomatic Medicine, Reproductive Medicine Research Group, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Mol Hum Reprod. 2017 Jul 1;23(7):509-519. doi: 10.1093/molehr/gax024.
What is the impact of chronic hypertension on placental development, fetal growth and maternal outcome in the stroke-prone spontaneously hypertensive rat (SHRSP)?
SHRSP showed an impaired remodeling of the spiral arteries and abnormal pattern of trophoblast invasion during placentation, which were associated with subsequent maternal glomerular injury and increased baseline hypertension as well as placental insufficiency and asymmetric fetal growth restriction (FGR).
A hallmark in the pathogenesis of preeclampsia (PE) is abnormal placentation with defective remodeling of the spiral arteries preceding the onset of the maternal syndrome. Pregnancies affected by chronic hypertension display an increased risk for PE, often associated with poor maternal and fetal outcomes. However, the impact of chronic hypertension on the placentation process as well as the nature of the factors promoting the development of PE in pregnant hypertensive women remain elusive.
STUDY DESIGN, SIZE, DURATION: Timed pregnancies [n = 5] were established by mating 10-12-week-old SHRSP and Wistar Kyoto (WKY, normotensive controls) females with congenic males. Maternal systolic blood pressures (SBPs) were recorded pre-mating, throughout pregnancy (GD1-19) and post-partum by the tail-cuff method. On selected dates, 24 h urine- and blood samples were collected, and animals were euthanized for isolation of implantation sites and kidneys for morphometrical analyses.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The 24 h proteinuria and the albumin:creatinine ratio were used for evaluation of maternal renal function. Renal injury was assessed on periodic acid Schiff, Masson's trichrome and Sirius red stainings. Placental and fetal weights were recorded on gestation day (GD)18 and GD20, followed by determination of fetal cephalization indexes and developmental stage, according to the Witschi scale. Morphometric analyses of placental development were conducted on hematoxylin-eosin stained tissue sections collected on GD14 and GD18, and complemented with immunohistochemical evaluation of isolectin B4 binding for assessment of placental vascularization. Analyses of vascular wall alpha actin content, perforin-positive natural killer (NK) cells and cytokeratin expression by immunohistochemistry were used for evaluation of spiral artery remodeling and trophoblast invasion.
SHRSP females presented significantly increased SBP records from GD13 to GD17 (SBPGD13 = 183.9 ± 3.9 mmHg, P < 0.005 versus baseline) and increased proteinuria at GD18 (P < 0.01 versus WKY). Histological examination of GD18 kidneys revealed glomerular enlargement and mesangial matrix expansion, which were not evident in pregnant WKY or age-matched virgin SHRSP. At GD20, SHRSP displayed a significant reduction of placental mass (P < 0.01 versus WKY) and signs of placental insufficiency (i.e. hypertrophy and reduced branching morphogenesis of the labyrinth layer), associated with decreased offspring weights and increased cephalization index (both P < 0.001 versus WKY) indicating asymmetric FGR. Notably, SHRSP placentas displayed an incomplete remodeling of spiral arteries starting as early as GD14, with luminal narrowing and reduced densities of perivascular NK cells followed by decreased infiltration of endovascular trophoblasts at GD18.
n/a.
LIMITATIONS, REASONS FOR CAUTION: A pitfall of the present study is the differences in the blood pressure profiles between rats and humans (i.e. unlike pregnancies affected by PE, blood pressure in SHRSP and other hypertensive rat models decreases pre-delivery), which limits extrapolation of the results.
Our findings provide new insights on the role of chronic hypertension as a risk factor for PE by interfering with early events during the placentation process. The SHRSP strain represents an attractive model for further studies aimed at addressing the relative contribution of intrinsic (i.e. placental) and extrinsic (i.e. decidual/vascular) factors to defective spiral artery remodeling in pregnancies affected by PE.
STUDY FUNDING AND COMPETING INTEREST(S): This work was supported by research grants from Fundación Florencio Fiorini to G.B., from Charité Stiftung to S.M.B. and University of Buenos Aires (UBACyt) to J.T. The authors have no competing interests to declare.
慢性高血压对自发性高血压卒中倾向大鼠(SHRSP)胎盘发育、胎儿生长和母婴结局的影响是什么?
SHRSP 在胎盘形成过程中螺旋动脉重塑受损,滋养细胞浸润模式异常,随后出现母体肾小球损伤和基础高血压增加,以及胎盘功能不全和胎儿生长受限(FGR)不对称。
子痫前期(PE)发病机制的一个标志是螺旋动脉的异常胎盘形成,其发生在母体综合征出现之前。受慢性高血压影响的妊娠显示出患 PE 的风险增加,通常与不良的母婴结局相关。然而,慢性高血压对胎盘形成过程的影响以及促进妊娠高血压妇女中 PE 发展的因素性质仍不清楚。
研究设计、大小、持续时间:通过交配 10-12 周龄的 SHRSP 和 Wistar Kyoto(正常血压对照)雌性与同基因雄性,建立了定时妊娠 [n = 5]。通过尾夹法记录母体收缩压(SBP),包括配种前、整个妊娠期间(GD1-19)和产后。在选定的日期收集 24 小时尿液和血液样本,并通过安乐死分离植入部位和肾脏进行形态计量学分析。
参与者/材料、设置、方法:使用 24 小时蛋白尿和白蛋白:肌酐比值评估母体肾功能。通过过碘酸希夫、马松三色和 Sirius 红染色评估肾损伤。在妊娠第 18 天和第 20 天记录胎盘和胎儿的重量,然后根据 Witschi 量表确定胎儿头部化指数和发育阶段。在妊娠第 14 天和第 18 天收集苏木精-伊红染色组织切片进行胎盘发育形态计量学分析,并通过异硫氰酸荧光素 B4 结合的免疫组织化学评估补充胎盘血管化。通过免疫组织化学评估血管壁α肌动蛋白含量、穿孔素阳性自然杀伤(NK)细胞和细胞角蛋白表达,评估螺旋动脉重塑和滋养细胞浸润。
SHRSP 雌性从 GD13 到 GD17(SBPGD13 = 183.9 ± 3.9 mmHg,P < 0.005 与基线相比)的 SBP 记录显著增加,并且在 GD18 时蛋白尿增加(P < 0.01 与 WKY 相比)。GD18 肾脏的组织学检查显示肾小球增大和系膜基质扩张,这在怀孕的 WKY 或同龄的 virgin SHRSP 中并不明显。在 GD20,SHRSP 显示胎盘质量显著降低(P < 0.01 与 WKY 相比)和胎盘功能不全的迹象(即迷路层的肥大和分支形态发生减少),与后代体重减轻和头部化指数增加(均 P < 0.001 与 WKY 相比)有关,表明胎儿生长受限不对称。值得注意的是,SHRSP 胎盘从 GD14 开始就出现螺旋动脉重塑不完全,表现为管腔狭窄和血管周围 NK 细胞密度降低,随后在 GD18 时血管内滋养细胞浸润减少。
无。
局限性、谨慎的原因:本研究的一个缺陷是大鼠和人类的血压谱存在差异(即与受 PE 影响的妊娠不同,SHRSP 和其他高血压大鼠模型的血压在分娩前降低),这限制了结果的推断。
我们的研究结果提供了新的见解,即慢性高血压通过干扰胎盘形成过程中的早期事件,作为 PE 的危险因素之一。SHRSP 株代表了进一步研究的有吸引力的模型,旨在解决 PE 受影响妊娠中螺旋动脉重塑缺陷的内在(即胎盘)和外在(即蜕膜/血管)因素的相对贡献。
这项工作得到了 Fundación Florencio Fiorini 对 G.B.、Charité Stiftung 对 S.M.B. 和 University of Buenos Aires(UBACyt)对 J.T.的研究资助。作者没有竞争利益需要申报。